

BS80 Disposable Plasma Bilirubin Perfusion Adsorption Column



Efficiently remove bilirubin and bile acid.

A plasma bilirubin perfusion adsorption column with a smaller blood volume.

Product Properties

Adsorbent Volume(ml)	80
Blood Volume(ml)	50±10
Adsorbent Material	Polystyrene Divinylbenzene Anion Exchange Resin
Sterilization Method	Moist Heat Sterilization
Housing Material	Polypropylene



Jafron Headquarters



CE



ISO 9001



EN ISO 13485

CY-BS80-01-10-2021-EN



JAFRON BIOMEDICAL CO., LTD.

Address: No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, China.

Tel: +86 (756) 3689708

E-mail: overseatrade@jafron.com

Website: en.jafron.com

(For Internal Use)



Stock Abbreviation: JFSW
Stock Code: 300529



BS80 Disposable Plasma Bilirubin Perfusion Adsorption Column

Special Adsorption of Bilirubin and Bile Acid


Small cartridge
Special care



Jafron Biomedical Co.,Ltd.

Clinical Indication

BS80 containing anion-exchange resin, can specially adsorb bilirubin and bile acid. It works effectively to relieve the symptoms of hyperbilirubinemia and hyperbileacidemia.



Smaller Blood Volume


The extracorporeal circulation blood volume (tube + column) in children's blood purification treatment should not exceed 10% (8ml/kg) of the child's total blood volume to avoid adverse reactions such as cardiopulmonary insufficiency and multiple organ failure.^[3, 4]



Smaller Blood Volume 50±10ml


Clinical Data

The treatments with the bilirubin adsorption column for children can reduce the patient's bilirubin level and improve biochemical indicators. The TBIL and DBIL decreased significantly after treatments, and the patients tolerated the treatments well.^[1]



After the artificial liver treatment in 23 PALF patients, the levels of ALT, TBil, blood ammonia, and lactic acid (Lac) in the patients were significantly reduced compared with those before treatment.^[2]

Observation on the curative effect of hybrid artificial liver technology in the treatment of children with PALF




*Contraindications, Warnings and Precautions refer to Instruction For Use.

References:

- [1] Zhang, H., Chu, J., Wang J., An, Y., Wang, Y. (2019). Observation on the curative effect of bilirubin adsorption in the treatment of three children with hyperbilirubinemia. Chinese Pediatric Emergency Medicine, 26(6): 470-471.
- [2] Zhang, Z., Sheng, C., Qi, J., Li, Y. (2015). Clinical analysis and prognostic judgment of artificial liver technology in the treatment of fulminant liver failure in children. Journal of Clinical Hepatology, 31 (8): 1262-1265.
- [3] Dang, X., Wu, Y. et al. (2018). Expert consensus on clinical application of hemoperfusion in children. Chinese Pediatric Emergency Medicine, 25 (8): 561-568.
- [4] Xu, X., Feng, Z. (2012). Interpretation of expert consensus on continuous blood purification in the treatment of severe sepsis in children. Chinese Journal of Pediatrics, 50(6): 684-688.

Jafron has been focusing on hemoadsorption therapy for more than 20 years.



Advanced resin

- Surface modification technology to improve blood compatibility
- High mechanical strength of adsorbents and large adsorptive surface area
- Nano-scale accurate molecular sieve control technology that enhances the effect of specific elimination of target substances



High standard production quality control

- The production system complies strictly with international quality certification CE, ISO, etc.
- Possess an international standard ISO 7 clean workshop and ISO 5 clean operation system
- Automatic production line



Clinical Application

- Clinical use for more than 20 years
- Used by over 6000 major hospitals in over 80 countries
- Benefited more than 3 million patients annually in the globe
- Support from 100+ peer reviewed international publications



Jafron Headquarters



CE



ISO 9001



EN ISO 13485

CY-HA60-01-10-2021-EN



JAFRON BIOMEDICAL CO., LTD.

Address: No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, China.

Tel: 0086-756-3689708

E-mail: overseatrade@jafron.com

Website: en.jafron.com

(For Internal Use)



Stock Abbreviation: JFSW
Stock Code: 300529

CE 0197



HA60 Disposable Hemoperfusion Cartridge

Improve The Acute Phase

Small cartridge
Special care




 Jafron Biomedical Co.,Ltd.

Clinical Application of Adsorption Therapy*

- Sepsis
- Allergic Purpura
- Cardiac Surgery
- Hyperinflammation
- Acute Poisoning
- Liver Failure
- Drug Overdose

*According to clinical experience, HA cartridge has been applied conditions above.

Clinical Efficacy of Adsorption Therapy



*The above data are from publications on hemoadsorption therapy.

Recommendation from Authorities

«Expert consensus on clinical application of hemoperfusion in children»

Hemoperfusion has a good effect on the treatment of children's acute poisoning caused by chemical poisons, paraquat, bee stings, and drug overdose, etc.^[2]

«Pediatric blood purification technique»

Conventional blood purification therapies such as high-flux hemodialysis and hemodiafiltration have low efficiency in removing medium and large molecular toxins in Septic patients, while hemoperfusion can remove uric acid, peptides and other medium molecular substances efficiently.^[5]

Smaller Blood Volume




Smaller Blood Volume 65±20ml


According to research, the extracorporeal circulation blood volume (tube + column) in children's blood purification treatment should not exceed 10% (8ml/kg) of the child's total blood volume to avoid adverse reactions such as cardiopulmonary insufficiency and multiple organ failure.^[2,4]

Compatible and Convenient Operation

Hemoperfusion therapy can be used alone or in conjunction with CRRT/HD/HDF^[7-8]



HP+CPB/ECMO^[9-10]



Product properties

Product Parameter	HA60 Disposable Hemoperfusion Cartridge
Adsorbent volume (ml)	60
Blood volume (ml)	65±20
Adsorbent material	Double Crosslinked Styrene-divinylbenzene Copolymers
Housing material	Polycarbonate
Sterilization method	Irradiation Sterilization

*Contraindications, Warnings and Precautions refer to Instruction For Use.

References:

- [1] Sun, X., Chen, X., Lu, J., Tao, Y., Zhang, L., Dong, Li. (2019). Extracorporeal treatment in children with acute severe poisoning [J]. Medicine (Baltimore), 98 (47): e18086.
- [2] Dang, X., Wu, Y. et al. (2018). Expert consensus on clinical application of hemoperfusion in children. Chinese Pediatric Emergency Medicine, 25 (8): 561-568.
- [3] Blood Purification Expert Committee of Pediatrician Branch of Chinese Medical Doctor Association (2018). Investigation on the current status of hemoperfusion in the treatment of severe allergic purpura in children. Chinese Pediatric Emergency Medicine [J], 25 (6): 429-433.
- [4] Xu, X., Feng, Z. (2012). Interpretation of expert consensus on continuous blood purification in the treatment of severe sepsis in children. Chinese Journal of Pediatrics, 50(6): 684-688.
- [5] Shen, Y., Yi, Z. (2012). Pediatric blood purification technique. Tsinghua University Press [M], Beijing, 2012: 129.
- [6] Zhao, H., Wang, S., Yang, Z., Liu, J. (2013). Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column. Therapeutic Apheresis and Dialysis, 17: 454-461.
- [7] Huang Bin, et al. Clinical study of continuous veno-venous hemofiltration combined with hemoperfusion in the treatment of severe burn sepsis. Journal of Clinical Emergency (China), 2019:1009-5918.
- [8] Sun, Shiren, et al. High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study. Annals of Saudi medicine 35.5 (2015): 352-358.
- [9] Zijian He, et al. The Efficacy of Resin Hemoperfusion Cartridge on Inflammatory Responses during Adult Cardiopulmonary Bypass. Blood Purif. 2021 Jun 9;1-7.
- [10] Prof. Claudio Ronco. CENTRO SPECIALIZZATO REGIONALE PER LE TERAPIE DIALITICHE NELL'INSUFFICIENZA RENALE ACUTA E CRONICA E PER LE TECNOLOGIE EXTRACORPOREE DI SUPPORTO MULTI-ORGANICO. 2020.